Abstract: Background: Although many therapeutic approaches have been attempted to treat spinal cord injury, cellular transplantation offers the greatest promise in reconstituting the architecture of the damaged cord. Methods: A literature review was conducted to search for clinical trials investigating stem cells as treatment for spinal cord injury in the United States. Results: Overall, eight studies met inclusion criteria. Of the included studies, four were identified as being terminated, suspended, or not yet recruiting. Two studies were identified as currently recruiting, including one phase one trial evaluating stereotactic injections of human spinal cord-derived neural stem cells in patients with chronic spinal cord injuries, and one trial of transplantation of autologous bone marrow derived stem cells via paraspinal injections, intravenous injections, and intranasal placement. One study was identified as an active study, a phase one trial of intrathecal injection of 100 million autologous, ex-vivo expanded, adipose-derived mesenchymal stem cells. One trial that was listed as completed is a phase 1/2a, dose escalation study, investigating stereotactic injection of human embryonic stem cell derived oligodendrocyte progenitor cells. Conclusions: Although few significant publications have emerged to this point, current trial results are promising.

Keywords: spinal cord injury; stem cell transplant; clinical trial

1. Introduction

The global incidence of spinal cord injury (SCI) ranges between 10.4 and 83 per million inhabitants per year [1,2]. Of these injuries approximately half result in complete neurologic injury and approximately 33% result in tetraplegia [1,2]. SCI has a male predilection and affects 3 to 4 times more males than females [1–3]. The mean age of patients at time of injury has increased from 29 in the 1970s to closer to 43 now [1,2,4]. This increase likely reflects the increase in mean age of the general population and greater number of spinal cord injuries that are occurring in elderly populations [2]. There is a significant geographic disparity in cases of SCI which may also be related to discrepancies in reporting [2,5]. A recent study found the incidence of SCI in North America to have increased from 43.3 to 51 per million inhabitants per year and to have increased in Europe from 13.9 to 19.4 per million inhabitants per year over the course of 30 years [1]. During this time frame, however, the prevalence of SCI in Europe and North America has remained fairly stable [1]. The most common cause of spinal cord injuries are motor vehicle collisions followed by falls (the leading cause in elderly patients), violent crime, and athletics.

Although many therapeutic approaches have been attempted, cellular transplantation offers the greatest promise in reconstituting the architecture of the damaged cord by providing a permissive substrate, replacing lost cells, enhancing tissue preservation, supporting axonal regeneration,
and modulating the inflammatory response. In particular, mesenchymal stem cells (derived from bone marrow, adipose tissue, or blood) have been reported to enhance neuroprotection, immunomodulation, sprouting, and axonal regeneration. Neural stem cells have also demonstrated these capacities, as well as the ability to form synapses between graft and host, and, in the case of cells directed toward a glial fate, remyelinate. This manuscript includes a review of clinical trials investigating stem cell transplantation for treatment for spinal cord injury.

2. Methods

A review of literature was conducted using online databases PubMed, the Cochrane Library, and clinicaltrials.gov to search for clinical trials investigating stem cell transplantation for treatment of spinal cord injury. Keywords “spinal cord injury” and “stem cell” were used to identify studies of interest. Additional manual searches through cited references were performed. Only clinical trials were included in further analysis. Cohort studies, case-control studies, non-English publications, editorials, conference abstracts, errata, book chapters, systematic reviews, meta-analyses, case reports, and case series were excluded. Patient expanded access investigational new drug (IND) studies were excluded. Clinical trials conducted outside of the United States were also excluded. For studies identified through clinicaltrials.gov without associated references, further searches through PubMed were conducted using the trial name and the name of referenced investigators. Studies were evaluated for trial status (terminated, active, recruiting, etc.), clinical trial phase, intervention model (method of group assignment), number of subjects, inclusion criteria, method of transplantation, and primary outcome.

3. Results

In total, 106 manuscripts were identified. Several trials were excluded for using non-cell-based therapies, such as Sovateltide and Methylprednisolone, for using non-stem cell-based therapies, such as transplantation of harvested Schwann cells, or for including non-human subjects. Two studies represented Individual patient expanded access investigational new drug (IND) studies and were excluded. Several studies were excluded for being conducted outside of the United States. Overall, eight studies met inclusion criteria (Table 1).

3.1. Terminated or Suspended Trials

Of the included studies, two were identified as being terminated. This included a phase one trial of intravenous infusion of autologous bone marrow progenitor cells in pediatric patients. The reason for termination was cited as primary investigator relocation. A literature search was conducted which identified several studies regarding transplantation of autologous bone marrow progenitor cells in patients following traumatic brain injury and one study concerning transplantation of autologous bone marrow progenitor cells for treatment of sensorineural hearing loss, however, no studies regarding transplantation for spinal cord injury [6–11].
| Identifier   | Trial Name                                                                 | Status              | Intervention                                      | Phase | Intervention Model | N  | Inclusion Criteria: Age (Years) | Inclusion Criteria: AIS Scale | Inclusion Criteria: Time from Injury | Transplantation | Primary Outcome                                                                 |
|--------------|----------------------------------------------------------------------------|---------------------|---------------------------------------------------|-------|--------------------|----|--------------------------------|-------------------------------|-----------------------------------|----------------|-------------------------------------------------------------------------------|
| NCT01328860 | Autologous Stem Cells for Spinal Cord Injury (SCI) in Children            | Terminated          | Autologous Bone Marrow Progenitor cells           | 1     | Single Group Assignment | 10 | 1–15                           | A–D                           | 6 months to 4 years                | Intravenous | AIS                                                                            |
| NCT01162915 | Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury | Suspended           | Autologous bone marrow-derived mesenchymal stem cells | 1     | Single Group Assignment | 10 | 18-65                          | A                            | 2 weeks to 60 months               | Intrathecal | Safety                                                                         |
| NCT03308565 | Adipose Stem Cells for Traumatic Spinal Cord Injury (CELLTOP)             | Active, not recruiting | Autologous, Adipose derived Mesenchymal Stem Cells | 1     | Single Group Assignment | 10 | >18                            | A–B                           | 2 weeks to 1 year                | Intrathecal | Incidence of acute adverse events                                              |
| NCT01772810 | Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI | Recruiting          | Human spinal cord-derived neural stem cell        | 1     | Single Group Assignment | 8  | 18-65                          | A                            | 1 year to 2 years                 | Intramedullary | Adverse events and clinically significant laboratory abnormalities             |
| NCT03225625 | Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study (SciAVR) | Recruiting          | Autologous bone marrow derived stem cells         | NA    | Parallel Assignment   | 40 | >18                            | A–D                           | NR                               | Paraspinal, Intravenous, Intranasal | AIS                                                                 |
| NCT02163876 | Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury | Terminated          | Human central nervous system stem cell            | 2     | Randomized Parallel Assignment | 31 | 18-60                          | B–C                           | >12 weeks                         | Intramedullary | ISNCSCI upper extremity motor scores                                           |
| NCT03979742 | Umbilical Cord Blood Cell Transplant into Injured Spinal Cord with Lithium Carbonate or Placebo Followed by Locomotor Training | Not yet recruiting  | Umbilical cord blood mononuclear stem cells       | 2     | Randomized Parallel Assignment | 27 | 18-60                          | A                            | >12 months                        | Intramedullary | Walking Index of Spinal Cord Injury (WISCI II)                                 |
| NCT02302157 | Dose Escalation Study of AST-OPC1 in Spinal Cord Injury                   | Completed           | Human embryonic stem cell derived oligodendrocyte progenitor cells | 1/2a  | Single Group Assignment | 25 | 18-69                          | A–B                           | 21–42 days                       | Intramedullary | Adverse events                                                                 |

**Table 1. Summary of included studies**
A second study was a phase two trial sponsored by StemCells, Inc, of intramedullary implantation, a route of infusion directly into the spinal cord, of human central nervous system stem cells (HuCNS-SC) in patients with cervical spinal cord injuries of at least 4 months duration. Only patients with American Spinal Injury Association Impairment Scale A and B (AIS A-B) injuries were included. Thirty-one patients were enrolled in two cohorts. The first cohort included six patients enrolled in a dose escalation study, which allows for the determination of a dosage safety window, with patients receiving $15 \times 10^6$ to $40 \times 10^6$ stem cells during transplantation [12,13]. The second cohort of patients included 11 patients who were randomized to intramedullary injections of $40 \times 10^6$ stem cells [12,13]. There were 18 serious adverse events (SAE) in 12 of the patients who underwent injections [12]. Patients were further assessed by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) upper extremity motor score (UEMS). Compared to controls, patients following transplantation showed greater improvements in UEMS however the difference was not statistically significant. The trial was ultimately terminated secondary to financial considerations. A second trial of patients with thoracic spinal cord injuries outside of the United States was also carried out prior to early termination for financial considerations. HuCNS-SC have also been investigated for treatment of Pelizaeus-Merzbacher disease, an x-linked recessive leukodystrophy that leads to hypomyelination in the central nervous system, and neuronal ceroid lipofuscinosis [14–16].

One study was identified that was suspended secondary to financial considerations. The study was a phase one trial of intrathecal infusion, a route of infusion into the subarachnoid space, of autologous bone marrow-derived mesenchymal stem cells. A literature search identified studies investigating transplantation of stem cells for treatment of myocardial and limb ischemia, however, no studies regarding transplantation for spinal cord injury [17–19].

3.2. Trials Currently in Recruitment

Two studies were identified as currently recruiting. One study, sponsored by Neuralstem Inc. (now rebranded as Seneca Biopharma Inc.), is a phase one trial with single group assignment evaluating stereotactic injections of human spinal cord-derived neural stem cells. The trial is evaluating patients with chronic (1 to 2 years post-injury) AIS A spinal cord injuries. As a phase one trial the primary outcome measure is adverse events and clinically significant laboratory abnormalities within the first six months following injection. In total, the study will include eight patients broken into two groups. The first four patients were treated following spinal cord injuries of the thoracic spine (T2–T12). The second four patients will be enrolled following injuries to the lower cervical spine (C5–C7). Prior to beginning the trial, the NSI-566 human neural stem cell line showed favorable results in in vitro and animal models and was approved for a phase one and two trial in the treatment of amyotrophic lateral sclerosis (ALS) [20–23]. The results of the ALS trial, which included dose escalation, showed spinal cord transplantation of human stem cells could be carried out in a safe manner at escalating doses in both the lumbar and cervical spine. Results from the first four patients, all thoracic, following transplantation for SCI are promising. No serious adverse events were reported in the first 18–27 months post-procedure, and two patients showed one to two levels of neurologic improvement [24].

Another study that is currently in recruitment, is a trial of transplantation of autologous bone marrow derived stem cells via bilateral paraspinal injections of cells at the level of the injury as well as superior and inferior to that spinal segment. Patients will also receive an intravenous injection and intranasal placement of stem cells. The trial has a parallel assignment model and will assign 40 patients to three treatment arms: treatment only, treatment + exoskeleton movement, and treatment + virtual reality visualization. A literature search identified studies investigating transplantation of stem cells for treatment of several ophthalmologic conditions, however, no studies regarding transplantation for spinal cord injury [25–33].
3.3. Active Studies

One active study that was identified is the CELLTOP trial, a phase one trial of intrathecal injection of 100 million autologous, ex-vivo expanded, adipose-derived mesenchymal stem cells. The trial is evaluating patients from two weeks to one year post-injury who are AIS A or AIS B for incidence of acute adverse events up to four weeks following transplantation. Previous in vitro and animal model studies have shown exceptionally promising results following transplantation of adipose derived mesenchymal stem cells [34–40]. A recent publication from the CELLTOP trial examined the first treated patient. The patient was initially an AIS A spinal cord injury following a surfing accident, however, improved to AIS C prior to enrollment in the trial. Following implantation, the patient did not suffer a safety issue or adverse event during 18 months of follow-up. The patient was also noted to show improvement in motor and sensory scores during the follow-up period [41].

3.4. Trials in Pre-Recruitment

One trial is listed as not yet recruiting. It is a phase two trial assessing injection of umbilical cord blood mononuclear stem cells into bilateral dorsal root entry zones above and below an area of chronic (>1 year) spinal cord injury. Twenty-seven patients will be randomized through parallel assignment to three groups. Both groups A and B will receive stem cell transplantation. Group A will further receive lithium carbonate (750 mg/day) whereas group B will receive a placebo. Lithium has been shown in vitro to stimulate stem cell proliferation, neurogenesis, and regeneration of long spinal tracts, and has been shown in an animal model to improve locomotor recovery after transplantation of umbilical cord blood mononuclear stem cells [42,43]. Group C is a control group. The trial was double blinded except for group C.

The trial followed phase one and two clinical trials which were conducted outside the United States. In the phase two trial, 20 patients with complete chronic spinal cord injuries were assigned to five treatment groups. The first three groups received escalating dosages of umbilical cord blood mononuclear stem cells. Group D received the dosage of group C with addition of a bolus of methylprednisolone (30 mg/kg). Group E received the dosage of group C with the addition of a bolus of methylprednisolone and a 6 week course of lithium carbonate. During the follow-up period, 68 adverse events were recorded, all resolved with routine therapies. Three patients in the phase two trial had severe adverse events including slow wound healing, cerebrospinal fluid leak and wound dehiscence, and deep venous thrombosis. AIS scores improved from A to B in two patients and from A to C in three patients. In comparison to baseline, patients showed statistically significant improvements in walking index of spinal cord injury scores and spinal cord independence measure scores as well as in bladder and bowel function. Differences among treatment groups were not significantly different [43].

3.5. Completed Trials

One trial that was listed as completed is a phase 1/2a, dose escalation study, investigating stereotactic injection of human embryonic stem cell derived oligodendrocyte progenitor cells. The study evaluated patients with AIS A or B cervical spinal cord injuries who were 21–42 days post-injury. Patients were assigned to one injection of 2 million or 10 million cells, or 2 injections of 10 million cells for a total of 20 million cells. The primary outcome assessed was the number of adverse events that occurred within one year of injection. There have been no significant adverse events to date, however, full results from the trial have not yet been published. Animal testing prior to clinical trials showed significant improvements in remyelination and recovery of motor function after transplantation of human embryonic stem cell derived oligodendrocyte progenitor cells at 7 days following spinal cord injury. These results were, however, not shown at 10 months post injury [44–47]. Although not yet published in the peer reviewed literature, public announcement by the sponsoring industry reported significant improvement in two-thirds of the patients. Results from an earlier phase 1 trial, in which
five patients with AIS A thoracic injuries underwent stereotactic transplantation between 7 and 14 days post-injury were positive. There were no surgical complications and no severe adverse events.

4. Discussion

A literature search was done to identify clinical trials conducted in the United States investigating stem cell transplantation for treatment of spinal cord injury. Laboratory testing and animal models were used to test each stem cell type prior to human clinical trials. This study included only trials registered in the United States with approval from the United States Food and Drug Administration (FDA). This was done in-order to investigate trials that had all gone through the same approval process, thus making results more standardized and directly comparable. Regulatory requirements outside the United States vary by region and are generally less stringent than FDA requirements [48]. In comparison to approval in the European Union, the approval process in the United States is also faster and more transparent. Whereas all non-published data in U.S. trials is available for review online and by request, in the European Union, non-published data is considered “commercially sensitive” [49].

Of the eight studies that met inclusion criteria two studies were terminated and one was suspended. Five studies remain that are currently in pre-recruitment, recruitment, active, or completed. Of the five studies, two included transplantation of mesenchymal stem cells including autologous, adipose derived cells, and autologous bone marrow derived cells. One study each included transplantation of neural stem cells, umbilical cord blood cells, and embryonic stem cell derived oligodendrocyte progenitor cells, respectively.

Several factors varied across studies including the method of cellular transplantation. The majority of included trials include intrathecal or intramedullary transplantation with intravenous administration being less common. Intravenous transplantation has the benefit of being the least invasive although also has the significant disadvantage of not directly implanting cells within the subarachnoid space. Intramedullary transplantation is the most invasive, has the greatest surgical risk, however, has the greatest potential for long-term engraftment [12]. It can be carried out in a free hand technique or through stereotactic implantation. There is no clear superiority between different transplantation methods at this time as few studies have directly compared them in human studies.

A majority of US trials in this literature search have shown promising results. The StemCells, Inc. trial showed feasibility of freehand intramedullary injection of human central nervous system stem cells. Following a successful dose escalation study, patients showed greater improvement in upper extremity motor score in the transplantation group prior to study termination. Results from the NeuralStem and CELLTOP trials are also promising although both trials have not shown full phase one data. Positive clinical results from the dose escalation study of AST-OPC1 are likely to lead to the first phase three trial in the United States of stem cell transplantation for SCI.

Author Contributions: Conceptualization, R.G.F. and B.T.D.; Methodology, R.G.F. and B.T.D.; Writing—original draft preparation, A.P.; Writing—review and editing, R.G.F., B.T.D., and A.P.; Supervision, R.G.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We would like to acknowledge the Rush University Department of Neurological Surgery research team for their help in this paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wyndaele, M.; Wyndaele, J.J. Incidence, prevalence and epidemiology of spinal cord injury: What learns a worldwide literature survey? Spinal Cord 2006, 44, 523–529. [CrossRef]
2. Witiw, C.D.; Fehlings, M.G. Acute spinal cord injury. J. Spinal Disord. Tech. 2015, 28, 202–210. [CrossRef]
3. Rowland, J.W.; Hawryluk, G.W.; Kwon, B.; Fehlings, M.G. Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. Neurosurg. Focus 2008, 25, E2. [CrossRef]
4. National Spinal Cord Injury Statistical Center. Facts and Figures at a Glance; University of Alabama at Birmingham: Birmingham, AL, USA, 2020.

5. Singh, A.; Tetreault, L.; Kalsi-Ryan, S.; Nouri, A.; Fehlings, M.G. Global prevalence and incidence of traumatic spinal cord injury. Clin. Epidemiol. 2014, 6, 309–331.

6. Harting, M.T.; Baumgartner, J.E.; Worth, L.L.; Ewing-Cobbs, L.; Gee, A.P.; Day, M.C.; Cox, C.S., Jr. Cell therapies for traumatic brain injury. Neurosurg. Focus 2008, 24, E18. [CrossRef]

7. Harting, M.T.; Jimenez, F.; Xue, H.; Fischer, U.M.; Baumgartner, J.; Dash, P.K.; Cox, C.S. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J. Neurosurg. 2009, 110, 1189–1197. [CrossRef]

8. Harting, M.T.; Sloan, L.E.; Jimenez, F.; Baumgartner, J.; Cox, C.S., Jr. Subacute neural stem cell therapy for traumatic brain injury. J. Surg. Res. 2009, 153, 188–194. [CrossRef]

9. Cox, C.S., Jr.; Baumgartner, J.E.; Harting, M.T.; Worth, L.L.; Walker, P.A.; Shah, S.K.; Ewing-Cobbs, L.; Hasan, K.M.; Day, M.C.; Lee, D.; et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery 2011, 68, 588–600. [CrossRef]

10. Liao, G.P.; Harting, M.T.; Hetz, R.A.; Shah, S.K.; Corkins, C.J.; Hughes, T.G.; Jimenez, F.; Kosmach, S.C.; Day, M.C.; Tsao, K.; et al. Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr. Crit. Care Med. 2015, 16, 245–255. [CrossRef]

11. Baumgartner, L.S.; Moore, E.; Shook, D.; Messina, S.; Day, M.C.; Green, J.; Nandy, R.; Seidman, M.; Baumgartner, J.E. Safety of Autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children. J. Audiol. Otol. 2018, 22, 209–222. [CrossRef]

12. Levi, A.D.; Okonkwo, D.O.; Park, P.; Jenkins, A.L., 3rd; Kurpad, S.N.; Parr, A.M.; Banab, B.; Kim, D.; Casha, S.; et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery 2018, 82, 562–575. [CrossRef] [PubMed]

13. Levi, A.D.; Anderson, K.D.; Okonkwo, D.O.; Park, P.; Bryce, T.N.; Kurpad, S.N.; Aarabi, B.; Hisieh, J.; Gant, K. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J. Neurotrauma 2019, 36, 891–902. [CrossRef] [PubMed]

14. Gupta, N.; Henry, R.G.; Strober, J.; Kang, S.M.; Lim, D.A.; Bucco, M.; Caverzasi, E.; Gaetano, L.; Mandelli, M.L.; Ryan, T.; et al. Neural stem cell engraftment and myelination in the human brain. Sci. Transl. Med. 2012, 4, 155ra37. [CrossRef]

15. Selden, N.R.; Al-Uzri, A.; Huhn, S.L.; Koch, T.K.; Sikora, D.M.; Nguyen- Driver, M.D.; Guillaume, D.J.; Koh, J.L.; Gulettein, S.H.; Anderson, J.C.; et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J. Neurosurg. Pediatr. 2013, 11, 643–652. [CrossRef]

16. Gupta, N.; Henry, R.G.; Kang, S.M.; Strober, J.; Lim, D.A.; Ryan, T.; Perry, R.; Farrell, J.; Ulman, M.; Rajalingam, R.; et al. Long-Term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for pelizaeus- merzbacher disease. Stem Cell Rep. 2019, 13, 254–261. [CrossRef]

17. Lasala, G.P.; Silva, J.A.; Gardner, P.A.; Minguell, J.J. Combination stem cell therapy for the treatment of severe limb ischemia: Safety and efficacy analysis. Angiology 2010, 61, 551–556. [CrossRef]

18. Lasala, G.P.; Silva, J.A.; Kusnick, B.A.; Minguell, J.J. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: A Phase I study. Cardiovasc. Revasc. Med. 2011, 12, 29–34. [CrossRef]

19. Allers, C.; Lasala, G.P.; Minguell, J.J. Presence of osteoclast precursor cells during ex vivo expansion of bone marrow-derived mesenchymal stem cells for autologous use in cell therapy. Cytotherapy 2014, 16, 454–459. [CrossRef]

20. Lu, P.; Wang, Y.; Graham, L.; McHale, K.; Gao, M.; Wu, D.; Brock, J.; Blesch, A.; Rosenzweig, E.S.; Havton, L.A.; et al. Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell 2012, 150, 1264–1273. [CrossRef]

21. van Gorp, S.; Leerink, M.; Kakinoana, O.; Platoshyn, O.; Santucci, C.; Galik, J.; Joosten, E.A.; Hruska-Plochan, M.; Goldberg, D.; Marsala, S.; et al. Amelioration of motor/sensory dysfunction and spasticity in a rat model of acute lumbar spinal cord injury by human neural stem cell transplantation. Stem Cell Res. Ther. 2013, 4, 57. [CrossRef]

22. Glass, J.D.; Hertzberg, V.S.; Bouulis, N.M.; Riley, J.; Federici, T.; Polak, M.; Bordeau, J.; Fournier, C.; Johe, K.; Hazel, T.; et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology 2016, 87, 392–400. [CrossRef]
23. Riley, J.; Federici, T.; Polak, M.; Kelly, C.; Glass, J.; Raore, B.; Taub, J.; Kesner, V.; Feldman, E.L.; Boulis, N.M. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: A phase 1 safety trial, technical note, and lumbar safety outcomes. *Neurosurgery* 2012, 71, 405–416, discussion 16. [CrossRef]

24. Curtis, E.; Martin, J.R.; Gabel, B.; Sidhu, N.; Rzesiewicz, T.K.; Mandeville, R.; Van Gorp, S.; Leerink, M.; Tadokoro, T.; Marsala, S.; et al. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. *Cell Stem Cell* 2018, 22, 941–950.e6. [CrossRef]

25. Weiss, J.N.; Levy, S.; Benes, S.C. Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: A case report of improvement in relapsing auto-immune optic neuropathy. *Neural Regen. Res.*** 2015, 10, 1507–1515.

26. Weiss, J.N.; Levy, S.; Malkin, A. Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: A preliminary report. *Neural Regen. Res.*** 2015, 10, 982–988.

27. Weiss, J.N.; Benes, S.C.; Levy, S. Stem Cell Ophthalmology Treatment Study (SCOTS): Improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment. *Neural Regen. Res.*** 2016, 11, 1512–1516. [CrossRef]

28. Weiss, J.N.; Levy, S.; Benes, S.C. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow-derived stem cells in the treatment of Leber’s hereditary optic neuropathy. *Neural Regen. Res.*** 2016, 11, 1685–1694.

29. Weiss, J.N.; Levy, S.; Benes, S.C. Stem Cell Ophthalmology Treatment Study: Bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION). *Stem Cell Investig.* 2017, 4, 94. [CrossRef]

30. Weiss, J.N.; Levy, S. Stem Cell Ophthalmology Treatment Study: Bone marrow derived stem cells in the treatment of Retinitis Pigmentosa. *Stem Cell Investig.* 2018, 5, 18. [CrossRef]

31. Weiss, J.N.; Levy, S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow derived stem cells in the treatment of Dominant Optic Atrophy. *Stem Cell Investig.* 2019, 6, 41. [CrossRef]

32. Weiss, J.N.; Levy, S. Dynamic light scattering spectroscopy of the retina-a non-invasive quantitative technique to objectively document visual improvement following ocular stem cell treatment. *Stem Cell Investig.* 2019, 6, 8. [CrossRef]

33. Weiss, J.N.; Levy, S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow derived stem cells in the treatment of Usher syndrome. *Stem Cell Investig.* 2019, 6, 31. [CrossRef]

34. Kang, S.K.; Shin, M.J.; Jung, J.S.; Kim, Y.G.; Kim, C.H. Autologous adipose tissue-derived stromal cells for treatment of spinal cord injury. *Stem Cells Dev.* 2006, 15, 583–594. [CrossRef]

35. Zhang, H.T.; Luo, J.; Sui, L.S.; Ma, X.; Yan, Z.J.; Lin, J.H.; Wang, Y.S.; Chen, Y.Z.; Jiang, X.D.; Xu, R.X. Effects of differentiated versus undifferentiated adipose tissue-derived stem cell grafts on functional recovery after spinal cord contusion. *Cell. Mol. Neurobiol.* 2009, 29, 1283–1292. [CrossRef]

36. Oh, J.S.; Ha, Y.; An, S.S.; Khan, M.; Pennant, W.A.; Kim, H.J.; Yoon, D.H.; Lee, M.; Kim, K.N. Hypoxia-preconditioned adipose tissue-differentiated mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. *Neurosci. Lett.* 2010, 472, 215–219. [CrossRef]

37. Oh, J.S.; Kim, K.N.; An, S.S.; Pennant, W.A.; Kim, H.J.; Gwak, S.J.; Yoon, D.H.; Lim, M.H.; Choi, B.H.; Ha, Y. Cotransplantation of mouse neural stem cells (mNSCs) with adipose tissue-derived mesenchymal stem cells improves mNSC survival in a rat spinal cord injury model. *Cell Transplant.* 2011, 20, 837–849. [CrossRef]

38. Oh, J.S.; Park, I.S.; Kim, K.N.; Yoon, D.H.; Kim, S.H.; Ha, Y. Transplantation of an adipose stem cell cluster in a spinal cord injury. *Neuroreport* 2012, 23, 277–282. [CrossRef]

39. Park, S.S.; Lee, Y.J.; Lee, S.H.; Lee, D.; Choi, K.; Kim, W.H.; Kweon, O.K.; Han, H.J. Functional recovery after spinal cord injury in dogs treated with a combination of Matrigel and neural-induced adipose-derived mesenchymal Stem cells. *Cytotherapy* 2012, 14, 584–597. [CrossRef]

40. Dasari, V.R.; Veeravalli, K.K.; Dinh, D.H. Mesenchymal stem cells in the treatment of spinal cord injuries: A review. *World J. Stem Cells* 2014, 6, 120–133. [CrossRef]

41. Bydon, M.; Dietz, A.B.; Goncalves, S.; Moinuddin, F.M.; Alvi, M.A.; Goyal, A.; Yolcu, Y.; Hunt, C.L.; Garlanger, K.L.; Del Fabro, A.S.; et al. CELLTOP clinical trial: First report from a phase 1 trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury. *Mayo Clin. Proc.* 2020, 95, 406–414. [CrossRef]
42. Deng, X.Y.; Zhou, R.P.; Lu, K.W.; Jin, D.D. Lithium chloride combined with human umbilical cord blood mesenchymal stem cell transplantation for treatment of spinal cord injury in rats. *Nan Fang Yi Ke Da Xue Xue Bao* 2010, 30, 2436–2439.

43. Zhu, H.; Poon, W.; Liu, Y.; Leung, G.K.; Wong, Y.; Feng, Y.; Ng, S.C.P.; Tsang, K.S.; Sun, D.T.F.; Yeung, D.K.; et al. Phase I–II clinical trial assessing safety and efficacy of umbilical cord blood mononuclear cell transplant therapy of chronic complete spinal cord injury. *Cell Transplant.* 2016, 25, 1925–1943. [CrossRef]

44. Keirstead, H.S.; Nistor, G.; Bernal, G.; Totoiu, M.; Cloutier, F.; Sharp, K.; Steward, O. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. *J. Neurosci.* 2005, 25, 4694–4705. [CrossRef]

45. Nistor, G.I.; Totoiu, M.O.; Haque, N.; Carpenter, M.K.; Keirstead, H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. *Glia* 2005, 49, 385–396. [CrossRef]

46. Priest, C.A.; Manley, N.C.; Denham, J.; Wirth, E.D., 3rd; Lebkowski, J.S. Preclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury. *Regen. Med.* 2015, 10, 939–958. [CrossRef]

47. Manley, N.C.; Priest, C.A.; Denham, J.; Wirth, E.D., 3rd; Lebkowski, J.S. Human embryonic stem cell-derived oligodendrocyte progenitor cells: Preclinical efficacy and safety in cervical spinal cord injury. *Stem Cells Transl. Med.* 2017, 6, 1917–1929. [CrossRef]

48. Nunley, P.D.; Coric, D.; Frank, K.A.; Stone, M.B. Cervical disc arthroplasty: Current evidence and real-world application. *Neurosurgery* 2018, 83, 1087–1106. [CrossRef]

49. Van Norman, G.A. Drugs and devices: Comparison of European and U.S. approval processes. *JACC Basic Transl. Sci.* 2016, 1, 399–412. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).